⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 4, 2025Open Access

Supplementary Figure S5 from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors

Min Wang Yanxing Chen Lin Tian Chenyi Wu Jiaying Chen Jiajia Hu Runjie Huang Yingnan Wang Jinling Zhang Xiaojun Ouyang Liqin Wang Ying Jin Qi Zhao Feng Wang Rui‐Hua Xu

View Full Paper

Ask AI

Bookmark

Share

Key Points

Vascular normalization improves antitumor efficacy of HDAC inhibitors combined with immunotherapy, and enhances treatment outcomes.
Key evidence indicates that anti-angiogenesis therapy significantly reverses vascular abnormalities apparent with HDAC inhibition.
This analysis utilized techniques to explore the effects of combined anti-angiogenesis and immunotherapy on solid tumors.
Findings suggest that integrating vascular normalization may improve therapeutic strategies against solid tumors.

Implication

Observational analysis shows enhanced antitumor efficacy with vascular normalization in solid tumors, suggesting potential for combined therapies.

Abstract

Anti-angiogenesis therapy reverses the vascular abnormalization caused by HDAC inhibitor

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Wang et al. (2025) studied this question.

synapsesocial.com/papers/68c18c089b7b07f3a061490a https://doi.org/10.1158/2159-8290.30050799

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure S3 from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors2025
2Supplementary Figure S9 from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors2025
3Supplementary Figure S6 from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors2025
4Supplementary Figure S2 from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors2025
5Supplementary Figure S7 from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors2025

More related papers

Supplementary Figure S1 from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors2025
Supplementary Figure S8 from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors2025
Supplementary Figure S4 from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors2025